Psychedelics, inflammation, and the brain: New insights into anxiety and depression

Psychedelic substances such as psilocybin, LSD and MDMA are known for their remarkable antidepressant and anxiolytic effects in research into therapy for depression, anxiety, and PTSD, among others. Recent scientific work suggests that these effects stem not only from direct neural influence, but also from neuro-immune interactions – the interaction between the nervous system and the immune system. Inflammation in the brain is linked to mood disorders, and suppressing such inflammatory processes can contribute to symptom improvement.

In this report, we examine three specific biological components in this context: EGFR (epidermal growth factor receptor), NR2F2 (nuclear receptor subfamily 2 group F member 2, also known as COUP-TFII) and meningeal monocytes. For each component, we discuss the relevant findings with psychedelics (psilocybin, LSD, MDMA), the possible mechanistic interactions, and the clinical relevance or implications for treatment.

EGFR (epidermal growth factor receptor) and psychedelics

EGFR is a receptor tyrosine kinase traditionally known for cell growth and cancer, but it has recently been shown that EGFR plays an important role in the brain regarding stress and inflammation in astrocytes. Astrocytes—star-shaped glial cells that provide support and modulation in the central nervous system—use EGFR signaling pathways to limit excessive neuroinflammation and stress responses.

Relevant findings from studies: Research in mice showed that short periods of mild stress caused little damage, but that chronic Stress led to a reduction in EGFR expression in astrocytes of the amygdala (the brain area for emotion processing). This decrease in EGFR was accompanied by increased inflammatory activity and an increase in anxiety and fear behavior. In other words: normally, astrocytic EGFR appears to be protective mechanism to be something that prevents stress from escalating into persistent anxiety, but with chronic stress this mechanism breaks down, triggering an inflammatory cascade and anxiety responses.

Psychedelic intervention can break this pattern. In the study by Wheeler et al. (2025), stressed mice were treated with psilocybin or MDMA. Remarkably enough the effects of stress reversed: the administration of these psychedelics prevented the usual inflammatory response Despite the reduced EGFR function. Specifically, a significant reduction was observed in the number of inflammatory cells around the brain, and the mice clearly exhibited less anxious/fear behavior after the psychedelics. In addition, analysis of human postmortem brain samples and cell lines showed that the EGFR signaling pathway is also disrupted in people with depression (abnormal to lower than in healthy people). This suggests that the mechanisms observed in animals may also play a role in human mood disorders.

Not only psilocybin and MDMA, but classic psychedelics in general (including LSD) appear to have an anti-inflammatory effect on the nervous system. For example, previous studies suggest that hallucinogens such as LSD possess potent anti-inflammatory properties and can regulate the activity of astrocytes. In vitro-work, for example, showed that LSD inhibits B-cell proliferation and strongly reduces the release of pro-inflammatory cytokines (IL-2, IL-4, IL-6). Such findings support the idea that LSD, like psilocybin, is capable of reducing neuroinflammation via serotonergic pathways (5-HT)2A-receptors on immune cells and glial cells). Although LSD was not directly tested in Wheeler's mouse models, it is plausible that LSD can exert similar neuroimmune effects given the similarities in action (agonism of 5-HT receptors).

Mechanistic interactions: EGFR on astrocytes functions as a kind of molecular brake on stress-induced neuroinflammation. With adequate EGFR activation, astrocytes limit “crosstalk” between neurons and immune cells, keeping inflammatory responses in the brain dampened. However, when chronic stress disrupts this EGFR signal, inflammatory factors are released that attract immune cells (such as monocytes) and stimulate neurons to exhibit anxiety behavior. Psychedelics appear to intervene in this network at multiple levels. First, they may directly or indirectly support astrocytic functions: through serotonin agonism, they may activate astrocytic 5-HT.2A-receptors, which can have a beneficial effect on growth factor pathways such as EGFR. Secondly lower Psychedelics the release of pro-inflammatory signals, resulting in fewer immune cells being recruited to the brain (see further meningeal monocytes). The net result is that the stress-induced neuron-glia-immune feedback loop is interrupted: inflammatory cells stay away, astrocytes retain their inhibitory function, and neurons fire fewer fear responses.

Clinical relevance: These findings represent a paradigm shift in our understanding of treatments for anxiety and depression. Traditional therapies focus primarily on neurotransmitters (such as serotonin) and neuronal networks. The insight that immune signaling pathways – particularly EGFR-mediated astrocyte-neuron interactions – are involved in psychiatric symptoms, suggests that a combined approach may be more effective. Psychedelics could embody such a dual approach, as they both alter consciousness via neuronal receptors, and Dampen inflammatory responses via the glial and immune systems. This opens the door to new treatments for chronic stress, anxiety disorders and depression which are aimed at restoring neuro-immune balance. Interestingly, it has even been suggested to explore psychedelics or derivatives thereof for purely inflammatory neurological disorders (such as neurodegenerative diseases), given their ability to “reset” inflammatory signals in the central nervous system. Naturally, caution is warranted – psychedelics are not a “miracle cure” for all inflammatory diseases – but the research does point to tissue-specific benefits and teaches us that it pays to look beyond just neurons when developing new therapies. In summary, the role of EGFR in this story emphasizes that it reprogramming neuroimmune circuits a promising strategy is to counter the pathological anxiety and depression response to chronic stress.

NR2F2 (COUP-TFII) and psychedelics

NR2F2 (nuclear receptor subfamily 2, group F, member 2), better known as COUP-TFII, is a orphan nuclear receptor which functions as a transcription factor. It plays a role in the development and function of limbic brain regions – for instance, COUP-TFII is important for the structural formation of the amygdala during embryonic development. In the adult brains of experimental animals, NR2F2 is expressed in neurons of the amygdala, among others, where it can influence gene programs that control emotional behavior. New research shows that NR2F2 is also involved in stress and anxiety mechanisms in collaboration with astrocytes and immune cells.

Relevant findings: In the previously mentioned mouse model of chronic stress (Wheeler et al. 2025), researchers discovered that a decrease in astrocytic EGFR not only caused local inflammation but also had effects on nearby neurons. In particular, NR2F2 in amygdala neurons identified as a crucial link. Due to the reduced EGFR signals in astrocytes, the neurons entered a pro-inflammatory environment, which led to activation of NR2F2-regulated gene expression which reinforces anxiety and fear behavior. One could say that NR2F2 acts here as an “anxiety switch” in neurons: when activated by inflammatory signals, it promotes the formation or perpetuation of fearful memories and behaviors.

Psychedelic substances were found to modulate this process. In stressed mice that psilocybin or MDMA received, the inflammatory cascade was disrupted, thereby preventing the activation of NR2F2 in neurons. Specifically, the researchers observed that psychedelics were able to suppress the initiation of NR2F2-dependent transcription programs (which are normally triggered by stress). As a result, NR2F2-mediated anxiety responses did not occur or occurred to a much lesser extent. This result is important because it suggests that the behavioral change under the influence of psychedelics (less anxiety) is partly due to the disabling a molecular fear mechanism in neurons. Although LSD was not explicitly investigated in these experiments, it is likely that classic psychedelics such as LSD would have similar effects, given their shared action via serotonergic receptors and the general anti-inflammatory properties of these substances. To date, however, there is still no direct in vivo Evidence published regarding LSD and NR2F2 interactions.

Mechanistic interactions: The interplay between astrocytes and neurons under stress thus involves a chain in which NR2F2 the neuronal executor is of an inflammatory signal. Normally, astrocytes keep the environment calm via EGFR and other mechanisms, but upon loss of that brake (during stress), neurons receive stimuli (for example, cytokines) that lead to increased expression of transcription factors such as NR2F2. Once activated, NR2F2 regulates the expression of target genes that increase neuronal excitability and synaptic plasticity in fear circuits, for example by promoting fear memory-formation. Interestingly, it is known from developmental biology that COUP-TFII (NR2F2) influences axonal conduction and connectivity in the amygdala via neuropilin genes. It is conceivable that in the adult amygdala, NR2F2 also brings about structural or functional changes when activated, which make the system more sensitive to fear stimuli.

Psychedelics primarily intervene in this. via the immune system. By suppressing the inflammatory response (see previous and following sections), the trigger for NR2F2 activation removed. In other words: psilocybin and MDMA prevented meningeal immune cells and astrocytes from sending a “distress signal” to the neurons, causing NR2F2 in the neurons to remain inactive and the formation of fear memories to fail. There is currently no indication that psychedelics directly bind to or regulate NR2F2; the effect is indirect, via modulation of upstream factors such as cytokines and growth factor signaling pathways.

Clinical relevance: The identification of NR2F2 as a factor in stress-induced anxiety opens new insights for the treatment of anxiety disorders and trauma. First of all, it offers a biomarker or mechanistic anchor: increased NR2F2 activity could serve as an indicator of neuroinflammatory stress damage in the amygdala. Therapies that inhibit this pathway could be useful. Although direct pharmacological inhibition of a transcription factor is challenging, small molecules exist in preclinical research that can inhibit COUP-TFII (these are being tested elsewhere in cancer research, among others). In theory, such an agent could reduce fear conditioning, but its specificity and side effects would need to be carefully examined.

A more practically relevant insight is that Psychedelic use in therapy may be effective partly because it suppresses this type of pathological gene expression.. This supports the broader proposition that in some patients with depression or PTSD, the immune system and inflammation are a driving force behind their symptoms. Psychedelics would therefore have a dual effect: they cause acute psychological breakthroughs. and press down the biochemical “fear switch”. For the clinic, this means that we might benefit from combinations of therapies – for example, psychedelic therapy and anti-inflammatory drugs – in stubborn cases of depression or anxiety with an inflammatory component. Additionally, this explains why patients in studies sometimes experience very long-lasting relief after one or two doses of psilocybin: not only the conscious experience, but also the brain-immune environment is possible. repaired to a less anxiety-prone state. Further clinical studies, for example measuring NR2F2-dependent genes in patients before and after psychedelics, should confirm this. Nevertheless, this finding emphasizes that immunomodulation is a valuable starting point in the treatment of neuropsychiatric disorders, complementary to the usual neurotransmitters.

Meningeal monocytes and psychedelics

Monocytes are white blood cells of the immune system that normally reside in the bloodstream and spleen, but can mature into macrophages in response to inflammatory stimuli and invade tissues. Meningeal monocytes refers specifically to monocytic immune cells that are in the opinions (the meninges surrounding the brain). The meninges contain a rich network of immune cells that act as guardians at the brain's border. Animal studies show that stress and disease activate this meningeal immune system, which can have a major impact on the brain (via the release of cytokines, chemokines, and other factors that stimulate the underlying neural tissues).

Relevant findings: As early as the 1990s, a link was suggested between monocytes and depression: depressed patients were found to have abnormal numbers and activity of monocytes, hinting at a role of the immune system in their symptoms. Recent animal models have elaborated this causal link more clearly. In the chronic stress model in mice, monocytes observed accumulating in the meninges of stressed animals. These immune cells were mobilized from the spleen to the meninges in response to stress-related inflammatory signals. Once around the brain, the monocytes secreted pro-inflammatory mediators (such as interleukins), which triggered an “emergency response” in the underlying brain tissue—particularly astrocytes and neurons in the amygdala. This mechanism contributed substantially to the worsening of anxiety and stress behavior in the animals. In other words, the presence of these meningeal monocytes was a key factor that escalated mild stress into pathological fear via neuroinflammation.

Psychedelic treatment in this model had a remarkable effect on the monocyte response. Administration of psilocybin or MDMA to the stressed mice prevented the accumulation of monocytes in the meninges. After a single dose of psychedelics, there was significantly less influx of immune cells into the meninges, and a decrease in local inflammatory factors was also measured. Furthermore, the behavior of the mice normalized: their anxiety levels dropped to nearly normal, despite the prior stress exposure. This suggests that psychedelics are a powerful immunomodulatory effect have: they “calm” the peripheral immune system, as it were, resulting in less inflammation in and around the brain and breaking the vicious cycle of stress → inflammation → anxiety.

From the human perspective, direct evidence for meningeal monocytes is scarcer (it is difficult to study immune cells in the meninges of living humans). However, there are indirect indications that something similar is at play: for instance, elevated inflammatory markers and shifts in peripheral immune cells (including monocytes) are regularly found in depressed and chronically stressed populations. Additionally, experimental studies in healthy volunteers show that psilocybin also affects humans anti-inflammatory effects sorts. Mason et al. (2023), for example, found that a single dose of psilocybin caused acute changes in cytokines and stress-related immunological markers, including a transient increase in the anti-inflammatory cytokine IL-10 and modulation of cortisol levels, followed by a normalization (or even improvement) of immune status in the weeks thereafter. This shows that psilocybin the immune system dynamic reforms, which may run parallel to the reduction of neuroinflammation observed in mice. MDMA is known to increase stress hormones (such as cortisol) in the short term, but at the same time has direct immune effects that anti-inflammatory are. Studies have reported that acute MDMA administration in vivo leads to suppression of pro-inflammatory cytokines (such as TNF-α, IL-1β) and a shift towards anti-inflammatory immunity. Human research with recreational MDMA users also shows that MDMA temporarily suppresses cell-mediated immunity and alters cytokine profiles (for example, lower IL-2 levels and higher anti-inflammatory TGF-β levels).

Mechanistic interactions: The interaction between meningeal monocytes and psychedelics largely takes place via cytokine and chemokine signaling. Under stress, brain astrocytes and resident immune cells secrete alarm substances (such as CCL2/MCP-1, a chemokine for monocytes) that attract monocytes from the spleen and bloodstream to the meninges. The monocytes present become activated and in turn produce molecules (IL-6, TNF-α, etc.) that promote inflammation and stimulate neural circuits to trigger fear responses. Psychedelics likely disrupt this process in several ways: (1) They influence the release of stress hormones and neurotransmitters that drive immune cell migration. E.g., serotonin agonists can directly inhibit chemotaxis or raise the activation threshold via receptors on immune cells. (2) As mentioned, psychedelics activate 5-HT2A-receptors on immune cells; it is known that this leads to the inhibition of NF-κB-pathways and consequently reduced production of cytokines such as IL-1β, IL-6, and TNF-α. LSD and psilocybin can therefore, via these receptors on monocytes/macrophages, anti-inflammatory gene expression profile induce. (3) MDMA works partly differently: it causes massive serotonin and dopamine release in the CNS and peripherally, which results in immunosuppressive effects via increased cortisol and adrenergic effects (cortisol suppresses immune cell functions). In addition, MDMA has a weak direct agonist effect on 5-HT1/2 receptors, which together yield a complex immune profile. The net result is in any case that fewer monocytes migrate and that the monocytes that are present are less inclined to adopt a pro-inflammatory profile. As a result, severe inflammatory signals are absent in the brain, giving the brain the chance to recover and function normally. Apart from their effect on immune cells themselves, psychedelics also improve the communication between immune cells and brain cellsOne could say that they lift the “fog” of inflammatory signals, so that astrocytes and neurons are no longer constantly alarmed. This is evident from the fact that after psychedelic administration, the astrocytes in the amygdala resumed normal activity and the neural fear circuit calmed down.

Clinical relevance: The role of meningeal monocytes emphasizes that depression, anxiety, and PTSD are not merely “neural” disorders, but that the immune system is a contributing factor. This insight aligns with a growing clinical interest in anti-inflammatory treatments for depression – consider research into COX-2 inhibitors, minocycline (an antibiotic with immunosuppressive properties), or cytokine inhibitors in depressed patients. Psychedelics could be viewed in this context as immunomodulatory therapiesThey reduce inflammation in a subtle, natural way, instead of roughly shutting down the immune system like classic immunosuppressants do. The result is potentially better tolerance and broader effects (both psychological and physical).

For the treatment of, for example, treatment-resistant depression or PTSD, this implies that we could screen for inflammation biomarkers (such as highly sensitive CRP, cytokines, or abnormal monocyte profiles) to determine who might benefit from a more immune-targeted approach. Psychedelic therapy could be particularly effective in that subgroup due to its dual mechanism of action. The question also arises whether combination treatments offer advantages: Psychedelics together with anti-inflammatory drugs theoretically, they could amplify each other's effects in reducing neuroinflammation. Furthermore, monitoring of immune cells during psychedelic therapy could provide new insights – for example, does the number of pro-inflammatory monocytes or their activity decrease in patients after psilocybin sessions? Recent studies in humans suggest that they do, but this is still in its infancy.

Finally, the neuroimmunological target of psychedelics may open avenues to treatments outside of psychiatry. Because meningeal monocytes are also involved in neurodegenerative diseases and autoimmune diseases of the brain (such as multiple sclerosis), it is speculated whether psychedelics or derivatives thereof could be used in the future to inhibit harmful inflammatory responses in the brain. Naturally, this requires rigorous research, but current findings at least demonstrate that manipulating immune cells at the edge of the brain has a powerful effect on behavior and mood.

Conclusion

Psychedelic substances appear to form a unique hybrid between psychotropic drugs and immunomodulators. They not only directly influence neuronal receptors that alter perception and mood, but also recalibrate the interaction between brain cells and the immune system. The components discussed illustrate this aptly:

1. EGFR on astrocytes functions as a protective mechanism against stress-related inflammation and forms a new target with which psychedelics can reverse the “inflamed brain state” in depression/anxiety.

2. NR2F2 In neurons, it emerges as a switch for anxiety behavior under the influence of inflammatory stimuli; by switching this off via immunosuppression, psychedelics can reduce deep-seated anxiety responses.

3. Meningeal monocytes Finally, they appear to play a key role as a bridge between peripheral stress signals and central neural changes. The fact that psychedelics counteract the mobilization of these cells to the brain, thereby normalizing both neuroinflammation and behavior, is particularly promising.

Collectively, these findings indicate that the treatment of psychiatric disorders can benefit from an integral approach to body and mind. Psychedelics show us that it Resetting disrupted neuroimmune circuits is possible. This could explain why, for example, a single psilocybin session provides long-lasting improvement: it is not only a psychological breakthrough, but also a biological “reset” of inflamed brain networks. Future research—both in animal models and clinical trials—will have to determine how best to translate these insights into safe and effective therapies. But it is clear that components such as EGFR, NR2F2, and meningeal monocytes deserve a place in the conversation about how psychedelic substances bring about their remarkable therapeutic effects at the intersection of anxiety, depression and neuroinflammation.

Sources: The above findings are based on recent publications, including a Nature-study (Wheeler et al., 2025) with accompanying commentaries, press summaries, as well as previous research articles and reviews on the anti-inflammatory effects of psychedelics. This integration of animal experimental and clinical data underscores the potential of psychedelics to achieve therapeutic effects in anxiety, depression, and neuroinflammatory disorders via diverse molecular and cellular pathways.